StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Total Liver Disease Franchise Product Sales by Quarter

Total Liver Disease Franchise Product Sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Total Liver Disease Franchise Product Sales: $877M in Q2 2026, up 10.3% from a year earlier. That is the highest of the 18 quarters on record here.

Latest, Q2 2026
877
Period ended Jun 30, 2026
Change on a year earlier
+10.3%
795 in Q2 2025
History
18 quarters
Since Q1 2022
Sources
13
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal Liver Disease Franchise Product Sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026877+10.3%Form 10-Q (filed 2026-08-06) ↗
Q1 2026Mar 31, 2026767+1.2%Form 10-Q (filed 2026-05-07) ↗
Q4 2025Dec 31, 2025845+17.5%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 2025819+11.7%Form 10-Q (filed 2025-11-07) ↗
Q2 2025Jun 30, 2025795-4.4%Form 10-Q (filed 2026-08-06) ↗
Q1 2025Mar 31, 2025758+2.8%Form 10-Q (filed 2026-05-07) ↗
Q4 2024Dec 31, 2024719+4.1%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 2024733+3.8%Form 10-Q (filed 2025-11-07) ↗
Q2 2024Jun 30, 2024832+17.0%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024737+9.2%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 2023691-0.4%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 2023706-10.4%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 2023711+4.3%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023675+6.3%Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022694–Form 10-K (filed 2025-02-28) ↗
Q3 2022Sep 30, 2022788–Form 10-Q (filed 2023-11-07) ↗

Breakdown

What makes up total Liver Disease Franchise Product Sales

Cite this data

StockData. (2026). Gilead Sciences Total Liver Disease Franchise Product Sales ($M), quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-total

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.